Nordea Investment Management AB Cuts Stock Holdings in Pfizer Inc. $PFE

Key Points

• Nordea Investment Management AB cut its stake in Pfizer by 20.9%, selling 1,274,180 shares and leaving it with 4,823,166 shares worth about $120.1 million (≈0.08% of the company) at quarter-end.
• Pfizer beat Q4 expectations with $0.66 EPS (vs. $0.57 est.) and $17.56 billion in revenue, though revenue was down 1.2% year-over-year and analysts forecast ~2.95 EPS for the fiscal year.
• Market sentiment is mixed: recent analyst moves include HSBC raising its target to $32 and Argus upgrading to buy, while the consensus remains a "Hold" with an average target of $28.14, alongside positive pipeline news such as the TALAPRO‑3 Phase 3 win for TALZENNA + XTANDI.

Nordea Investment Management AB cut its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 20.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,823,166 shares of the biopharmaceutical company's stock after selling 1,274,180 shares during the period. Nordea Investment Management AB owned about 0.08% of Pfizer worth $120,073,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer in the 3rd quarter valued at about $29,000. Howard Hughes Medical Institute purchased a new position in shares of Pfizer in the 2nd quarter valued at about $30,000. Darwin Wealth Management LLC acquired a new position in shares of Pfizer during the second quarter worth about $32,000. True Wealth Design LLC increased its stake in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 974 shares during the period. Finally, Sagard Holdings Management Inc. purchased a new stake in shares of Pfizer during the second quarter worth approximately $36,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.98 on Monday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The firm's 50 day moving average is $26.68 and its two-hundred day moving average is $25.61. The firm has a market capitalization of $153.41 billion, a P/E ratio of 19.84 and a beta of 0.47.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the previous year, the firm earned $0.63 EPS. The company's revenue was down 1.2% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent research reports. UBS Group began coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a "neutral" rating and a $25.00 price target for the company. HSBC increased their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. Barclays began coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an "underweight" rating and a $25.00 price objective for the company. Argus upgraded shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 target price for the company in a research note on Monday, March 2nd. Finally, BMO Capital Markets reissued an "outperform" rating and issued a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $28.14.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Topline Phase 3 win for TALZENNA (talazoparib) + XTANDI: the TALAPRO-3 study met its primary endpoint, showing a significant delay in radiographic progression-free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a meaningful commercial and clinical win for Pfizer's oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Additional oncology progress: a Phase II study of atirmociclib in second‑line metastatic breast cancer hit its primary endpoint, supporting pipeline diversification beyond vaccines and COVID-era revenues. PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst interest/upgrade flow: recent analyst upgrades and a bullish HSBC forecast have lent buy‑side support and renewed attention to Pfizer’s valuation and upside potential. Pfizer NYSE: PFE Stock Price Up 3.2% Following Analyst Upgrade
• Neutral Sentiment: Pfizer-linked investment activity: Earendil Labs closed a $787M financing that included participation from a biotech development fund associated with Pfizer — a sign of strategic R&D/venture exposure but not an immediate earnings driver. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Market commentary and valuation focus: several recent pieces reassess Pfizer’s valuation and compare it to peers (e.g., Moderna), keeping the stock in investors’ screens but creating mixed sentiment around near‑term upside. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Unsolicited mini‑tender offer: Tutanota LLC filed a conditional mini‑tender to buy up to 1M Pfizer shares at $32 — Pfizer has advised shareholders to reject it. The offer is unlikely to be material but can create short‑term trading noise. Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.